Cytogen, Inc.

A217330

KR7217330000

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
10,250 ^KRW	-8.15%		-12.77%	-24.19%

Mar. 20	Cytogen, Inc. announced that it has received KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	CI
Mar. 18	Cytogen, Inc. announced that it expects to receive KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	CI

Cytogen, Inc. has filed an IPO.

February 20, 2018 at 12:00 am EST

Cytogen, Inc. has filed an IPO. Security Name: Shares Security Type: Common Stock PriceRange: KRW 20000 to KRW 22000

Latest news about Cytogen, Inc.

Cytogen, Inc. announced that it has received KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	Mar. 19	CI
Cytogen, Inc. announced that it expects to receive KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	Mar. 17	CI
Cytogen, Inc. announced that it has received KRW 55.49999 billion in funding from CanDx Holdings Limited	Dec. 27	CI
Cytogen, Inc. announced that it expects to receive KRW 99.999821616 billion in funding from Candx Holdings Limited	Dec. 27	CI
Candx Holdings Limited agreed to acquire a 31.96% stake in Cytogen, Inc. from Jeon Byung Hee and others for KRW 110 billion	Dec. 18	CI
Cytogen, Inc. announces tranche update	23-10-26	CI
Cytogen Raising KRW10 Billion to Finance Operations	23-09-27	MT
Cytogen, Inc. announced that it expects to receive KRW 69.99999 billion in funding from Excelsior Capital Korea Limited	23-09-25	CI
Cytogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-17	CI
Cytogen, Inc.(KOSDAQ:A217330) added to S&P Global BMI Index	21-09-20	CI
TSD Life Sciences Co.,Ltd. announced that it has received KRW 2.9999853 billion in funding from Cytogen, Inc.	21-05-20	CI
TSD Life Sciences Co.,Ltd. announced that it has received KRW 2.9999853 billion in funding from Cytogen, Inc.	21-05-20	CI
Cytogen, Inc. announced that it has received KRW 30 billion in funding	21-05-19	CI
Cytogen, Inc. announced that it expects to receive KRW 30 billion in funding	21-05-16	CI
TSD Life Sciences Co.,Ltd. announced that it expects to receive KRW 2.9999853 billion in funding from Cytogen, Inc.	21-05-16	CI
Cytogen, Inc. announced that it has received KRW 10 billion in funding	20-09-24	CI
Cytogen, Inc. announced that it expects to receive KRW 10 billion in funding	20-09-03	CI
Well Marker Bio Co., Ltd. announced that it has received KRW 18 billion in funding from a group of investors	19-07-07	CI
Cytogen, Inc. has completed an IPO in the amount of KRW 20.4 billion.	18-11-21	CI
Cytogen, Inc. has filed an IPO.	18-02-20	CI
Cytogen, Inc. has withdrawn its IPO.	18-02-19	CI
Cytogen, Inc. has filed an IPO.	15-10-08	CI

Cytogen Inc is a Korea-based company mainly engaged in the provision of liquid biopsy application services. The liquid biopsy application services include biomarker discovery and verification services, as well as liquid biopsy-based precision medical services which is the commercialization of companion diagnostics (CDx) development, among others. The biomarker discovery and verification services include circulating tumor cell (CTC)-based biomarker discovery and validation, gene mutation and transcript expression analysis, and drug testing and analysis services, among others. The liquid biopsy-based precision healthcare services include companion diagnosis, re-selection of therapeutic drugs, examination and treatment effectiveness monitoring, and recurrence prediction services, among others. In addition, the Company develops and sells platforms and kits for liquid biopsy. The Company distributes its products within the domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
CYTOGEN, INC.	-24.19%	168M
EXACT SCIENCES CORPORATION	-27.66%	9.88B
IOVANCE BIOTHERAPEUTICS, INC.	+26.94%	2.89B
BGI GENOMICS CO., LTD.	-15.73%	2.12B
VERACYTE, INC.	-20.83%	1.67B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+67.18%	1.45B
CAREDX, INC	+26.08%	788M
SEEGENE, INC.	-4.15%	741M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-28.78%	514M
CURIOX BIOSYSTEMS CO., LTD	+3.98%	308M

Bio Diagnostics & Testing

Cytogen, Inc.

Equities

A217330

KR7217330000

Biotechnology & Medical Research

Cytogen, Inc. has filed an IPO.

Latest news about Cytogen, Inc.

Chart Cytogen, Inc.

Company Profile

Income Statement Evolution

Sector Bio Diagnostics & Testing